Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

An unusual case of abdominal mycobacterial infection: Case report and literature review.

Ekermans P, de Gama R, Kock C, Hoosien E, Slavik T, Marshall T, Corcoran C, van Ingen J.

South Afr J HIV Med. 2019 Aug 28;20(1):993. doi: 10.4102/sajhivmed.v20i1.993. eCollection 2019.

2.

INNO-LiPA DNA line probe assay misidentification of M. smegmatis as Mycobacterium fortuitum complex.

van den Broek T, Janssen NG, Hetem DJ, Bekers W, Kamst M, Fluit AC, van Ingen J, Kusters JG, Rentenaar RJ.

Diagn Microbiol Infect Dis. 2019 Jun 24:114858. doi: 10.1016/j.diagmicrobio.2019.06.010. [Epub ahead of print]

PMID:
31358343
3.

Same meat, different gravy: ignore the new names of mycobacteria.

Tortoli E, Brown-Elliott BA, Chalmers JD, Cirillo DM, Daley CL, Emler S, Floto RA, Garcia MJ, Hoefsloot W, Koh WJ, Lange C, Loebinger M, Maurer FP, Morimoto K, Niemann S, Richter E, Turenne CY, Vasireddy R, Vasireddy S, Wagner D, Wallace RJ Jr, Wengenack N, van Ingen J.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900795. doi: 10.1183/13993003.00795-2019. Print 2019 Jul. No abstract available.

PMID:
31296783
4.

The differential effect of clarithromycin and azithromycin on induction of macrolide resistance in Mycobacterium abscessus.

Schildkraut JA, Pennings LJ, Ruth MM, de Brouwer AP, Wertheim HF, Hoefsloot W, de Jong A, van Ingen J.

Future Microbiol. 2019 Jun;14:749-755. doi: 10.2217/fmb-2018-0310. Epub 2019 Jul 4.

PMID:
31271060
5.

Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus.

Ruth MM, van Rossum M, Koeken VACM, Pennings LJ, Svensson EM, Ruesen C, Bowles EC, Wertheim HFL, Hoefsloot W, van Ingen J.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00449-19. doi: 10.1128/AAC.00449-19. Print 2019 Sep.

PMID:
31262763
6.

Non-tuberculous mycobacterial pulmonary disease.

Cowman S, van Ingen J, Griffith DE, Loebinger MR.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900250. doi: 10.1183/13993003.00250-2019. Print 2019 Jul.

PMID:
31221809
7.

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections.

Banaschewski B, Verma D, Pennings LJ, Zimmerman M, Ye Q, Gadawa J, Dartois V, Ordway D, van Ingen J, Ufer S, Stapleton K, Hofmann T.

J Cyst Fibros. 2019 Sep;18(5):714-720. doi: 10.1016/j.jcf.2019.05.013. Epub 2019 May 25.

PMID:
31138497
8.

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, Hoefsloot W, Pennings L, Koeken VACM, Wertheim HFL, Lee PS, van Ingen J, Deshpande D.

J Antimicrob Chemother. 2019 Jul 1;74(7):1952-1961. doi: 10.1093/jac/dkz143.

PMID:
31039251
9.

Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease.

Huiberts A, Zweijpfenning SMH, Pennings LJ, Boeree MJ, van Ingen J, Magis-Escurra C, Hoefsloot W.

Eur Respir J. 2019 Jul 11;54(1). pii: 1802143. doi: 10.1183/13993003.02143-2018. Print 2019 Jul. No abstract available.

PMID:
31000680
10.

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease.

Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900118. doi: 10.1183/13993003.00118-2019. Print 2019 Jul. No abstract available.

PMID:
31000671
11.

Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?

Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escurra C, van der Lee H, Verweij PE, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900117. doi: 10.1183/13993003.00117-2019. Print 2019 Jul. No abstract available.

PMID:
30956203
12.

M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis.

Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ.

Eur Respir J. 2019 Jul 11;54(1). pii: 1801991. doi: 10.1183/13993003.01991-2018. Print 2019 Jul.

PMID:
30880280
13.

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C.

PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.

14.

A case promoting use of ultrasound-guided sampling techniques to correctly diagnose MDR-TB in children.

van Aerde KJ, van der Heijden EHFM, Henriet SS, Merkus PJ, Magis-Escurra C, Hoefsloot W, van Ingen J, van der Flier M.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):236-238. doi: 10.5588/ijtld.18.0322.

PMID:
30808457
15.

Implementation of Semiautomated Antimicrobial Susceptibility Interpretation Hardware for Nontuberculous Mycobacteria May Overestimate Susceptibility.

Rockland M, Ruth MM, Aalders N, Pennings L, Hoefsloot W, Wattenberg M, van Ingen J.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01756-18. doi: 10.1128/JCM.01756-18. Print 2019 Apr.

16.

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.

J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.

PMID:
30649327
17.

Successful lung transplantation for chronic Mycobacterium abscessus infection in advanced cystic fibrosis, a case series.

Raats D, Lorent N, Saegeman V, Vos R, van Ingen J, Verleden G, Van Raemdonck D, Dupont L.

Transpl Infect Dis. 2019 Apr;21(2):e13046. doi: 10.1111/tid.13046. Epub 2019 Jan 13.

PMID:
30597699
18.

Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

Zweijpfenning SMH, van Groningen H, van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, Bax H, Andrejak C, Wener R, Rahman A, Kunst H, Lorent N, Brouwer MA, Hoefsloot W; NTM-NET.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801386. doi: 10.1183/13993003.01386-2018. Print 2018 Nov. No abstract available.

PMID:
30385602
19.

A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review.

van Ingen J, Turenne CY, Tortoli E, Wallace RJ Jr, Brown-Elliott BA.

Int J Syst Evol Microbiol. 2018 Nov;68(11):3666-3677. doi: 10.1099/ijsem.0.003026. Epub 2018 Sep 19.

PMID:
30231956
20.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.

PMID:
30216086
21.

Dissemination of localized Mycobacterium malmoense infection in an immunocompromised patient.

Zweijpfenning SMH, Schipper L, Duurkens VAM, Harbers JB, van Ingen J, Hoefsloot W.

Int J Infect Dis. 2018 Nov;76:35-37. doi: 10.1016/j.ijid.2018.08.019. Epub 2018 Sep 7.

22.

Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease.

Ruth MM, Sangen JJN, Pennings LJ, Schildkraut JA, Hoefsloot W, Magis-Escurra C, Wertheim HFL, van Ingen J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01208-18. doi: 10.1128/AAC.01208-18. Print 2018 Oct.

23.

The stability of antimycobacterial drugs in media used for drug susceptibility testing.

Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):305-308. doi: 10.1016/j.diagmicrobio.2018.06.015. Epub 2018 Jun 27.

PMID:
30025972
24.

Mycobacterium avium complex bacteria remain viable in sputum during storage and refrigeration.

Pennings LJ, Zweijpfenning S, Ruth MM, Wattenberg M, Boeree MJ, Hoefsloot W, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):309-310. doi: 10.1016/j.diagmicrobio.2018.06.017. Epub 2018 Jun 27.

PMID:
30025970
25.

Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania.

Ruesen C, Riza AL, Florescu A, Chaidir L, Editoiu C, Aalders N, Nicolosu D, Grecu V, Ioana M, van Crevel R, van Ingen J.

Sci Rep. 2018 Jun 26;8(1):9676. doi: 10.1038/s41598-018-27962-5.

26.

Can epilepsy be treated by antibiotics?

Braakman HMH, van Ingen J.

J Neurol. 2018 Aug;265(8):1934-1936. doi: 10.1007/s00415-018-8943-3. Epub 2018 Jun 21.

PMID:
29931545
27.

Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease.

Bakuła Z, Kościuch J, Safianowska A, Proboszcz M, Bielecki J, van Ingen J, Krenke R, Jagielski T.

Respir Med. 2018 Jun;139:91-100. doi: 10.1016/j.rmed.2018.05.007. Epub 2018 May 9.

PMID:
29858008
28.

MALDI Spectra Database for Rapid Discrimination and Subtyping of Mycobacterium kansasii.

Murugaiyan J, Lewin A, Kamal E, Bakuła Z, van Ingen J, Ulmann V, Unzaga Barañano MJ, Humięcka J, Safianowska A, Roesler UH, Jagielski T.

Front Microbiol. 2018 Apr 3;9:587. doi: 10.3389/fmicb.2018.00587. eCollection 2018.

29.

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.

van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800170. doi: 10.1183/13993003.00170-2018. Print 2018 Mar. No abstract available.

30.

Molecular typing of Mycobacterium kansasii using pulsed-field gel electrophoresis and a newly designed variable-number tandem repeat analysis.

Bakuła Z, Brzostek A, Borówka P, Żaczek A, Szulc-Kiełbik I, Podpora A, Parniewski P, Strapagiel D, Dziadek J, Proboszcz M, Bielecki J, van Ingen J, Jagielski T.

Sci Rep. 2018 Mar 13;8(1):4462. doi: 10.1038/s41598-018-21562-z.

31.

Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Bakuła Z, Modrzejewska M, Pennings L, Proboszcz M, Safianowska A, Bielecki J, van Ingen J, Jagielski T.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01788-17. doi: 10.1128/AAC.01788-17. Print 2018 Apr.

32.

Escherichia hermannii as the sole pathogen in urosepsis: case report.

Haasdijk RA, van Ingen J.

New Microbes New Infect. 2017 Nov 22;21:100-101. doi: 10.1016/j.nmni.2017.11.005. eCollection 2018 Jan. No abstract available.

33.

How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry.

Alcaide F, Amlerová J, Bou G, Ceyssens PJ, Coll P, Corcoran D, Fangous MS, González-Álvarez I, Gorton R, Greub G, Hery-Arnaud G, Hrábak J, Ingebretsen A, Lucey B, Marekoviċ I, Mediavilla-Gradolph C, Monté MR, O'Connor J, O'Mahony J, Opota O, O'Reilly B, Orth-Höller D, Oviaño M, Palacios JJ, Palop B, Pranada AB, Quiroga L, Rodríguez-Temporal D, Ruiz-Serrano MJ, Tudó G, Van den Bossche A, van Ingen J, Rodriguez-Sanchez B; European Study Group on Genomics and Molecular Diagnosis (ESGMD).

Clin Microbiol Infect. 2018 Jun;24(6):599-603. doi: 10.1016/j.cmi.2017.11.012. Epub 2017 Nov 22. Review.

34.

New insights in the treatment of nontuberculous mycobacterial pulmonary disease.

Ruth MM, van Ingen J.

Future Microbiol. 2017 Oct;12:1109-1112. doi: 10.2217/fmb-2017-0144. Epub 2017 Sep 20. No abstract available.

35.

Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.

Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W.

Respir Med. 2017 Oct;131:220-224. doi: 10.1016/j.rmed.2017.08.031. Epub 2017 Sep 1.

PMID:
28947034
36.

Treatment of Mycobacterium avium-intracellulare complex: a great leap forward.

Alffenaar JC, van Ingen J.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i1-i2. doi: 10.1093/jac/dkx310. No abstract available.

PMID:
28922812
37.

Reinstating Mycobacterium massiliense and Mycobacterium bolletii as species of the Mycobacterium abscessus complex.

Adekambi T, Sassi M, van Ingen J, Drancourt M.

Int J Syst Evol Microbiol. 2017 Aug;67(8):2726-2730. doi: 10.1099/ijsem.0.002011. Epub 2017 Aug 18.

PMID:
28820087
38.

Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.

van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafrańska A, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Rüegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Höller C, Debast SB, Wolfhagen MJ, Hopman J, Kluytmans J, Langelaar M, Notermans DW, Ten Oever J, van den Barselaar P, Vonk ABA, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith EG, Zambon M, Serr A, Götting T, Ebner W, Thürmer A, Utpatel C, Spröer C, Bunk B, Nübel U, Bloemberg GV, Böttger EC, Niemann S, Wagner D, Sax H.

Lancet Infect Dis. 2017 Oct;17(10):1033-1041. doi: 10.1016/S1473-3099(17)30324-9. Epub 2017 Jul 12.

PMID:
28711585
39.

Nifurtimox Is Ineffective against Drug-Resistant Mycobacteria.

Ruth MM, Sangen JJN, Wertheim HFL, van Ingen J.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01233-17. doi: 10.1128/AAC.01233-17. Print 2017 Sep. No abstract available.

40.

Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review.

Hase I, Morimoto K, Sakagami T, Ishii Y, van Ingen J.

Diagn Microbiol Infect Dis. 2017 Aug;88(4):308-315. doi: 10.1016/j.diagmicrobio.2017.05.011. Epub 2017 May 18. Review.

PMID:
28633901
41.

Draft Genome Sequences of Mycobacterium kansasii Clinical Strains.

Borówka P, Lach J, Bakuła Z, van Ingen J, Safianowska A, Brzostek A, Dziadek J, Strapagiel D, Jagielski T.

Genome Announc. 2017 Jun 1;5(22). pii: e00406-17. doi: 10.1128/genomeA.00406-17.

42.

Disseminated Mycobacterium abscessus infection in a peritoneal dialysis patient.

Mooren VHJF, Bleeker MWP, van Ingen J, Hermans MHA, Wever PC.

IDCases. 2017 May 4;9:6-7. doi: 10.1016/j.idcr.2017.05.001. eCollection 2017.

43.

Correction: High Rates of Non-Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis.

López-Varela E, García-Basteiro AL, Augusto OJ, Fraile O, Bulo H, Ira T, Gondo K, van Ingen J, Naniche D, Sacarlal J, Alonso PL.

PLoS One. 2017 Apr 6;12(4):e0175613. doi: 10.1371/journal.pone.0175613. eCollection 2017.

44.

Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases.

van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE; NTM-NET.

Eur Respir J. 2017 Feb 15;49(2). pii: 1601855. doi: 10.1183/13993003.01855-2016. Print 2017 Feb. No abstract available.

45.

MST1R mutation as a genetic cause of Lady Windermere syndrome.

Becker KL, Arts P, Jaeger M, Plantinga TS, Gilissen C, van Laarhoven A, van Ingen J, Veltman JA, Joosten LA, Hoischen A, Netea MG, Iseman MD, Chan ED, van de Veerdonk FL.

Eur Respir J. 2017 Jan 18;49(1). pii: 1601478. doi: 10.1183/13993003.01478-2016. Print 2017 Jan. No abstract available.

46.

High Rates of Non-Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis.

López-Varela E, García-Basteiro AL, Augusto OJ, Fraile O, Bulo H, Ira T, Gondo K, van Ingen J, Naniche D, Sacarlal J, Alonso PL.

PLoS One. 2017 Jan 17;12(1):e0169757. doi: 10.1371/journal.pone.0169757. eCollection 2017. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175613.

47.

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA.

Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156.

48.

Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria.

Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van Ingen J, Cambau E.

Clin Microbiol Infect. 2017 Mar;23(3):167-172. doi: 10.1016/j.cmi.2016.09.006. Epub 2016 Sep 21. Review.

49.

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.

50.

Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology.

Jankovic M, Sabol I, Zmak L, Jankovic VK, Jakopovic M, Obrovac M, Ticac B, Bulat LK, Grle SP, Marekovic I, Samarzija M, van Ingen J.

Int J Tuberc Lung Dis. 2016 Jul;20(7):934-40. doi: 10.5588/ijtld.15.0633.

PMID:
27287647

Supplemental Content

Loading ...
Support Center